![](https://images.squarespace-cdn.com/content/v1/636934fdbb8bde6edeb455cd/5fdbc780-5a63-48ab-9fd3-ccdf6f4b608e/Verpora-Knowledge-bg.jpg)
Knowledge & Resources
Expert insights and knowledge on global Innovative Contracting, VBA,
Market Access and Human Performance Factors
Innovative Contracting & VBA
Articles & Whitepapers
![Announcements from South Korea (SK) to Denmark (DK) pave the way for further outcomes-based contracting for high-cost oncology drugs](https://images.squarespace-cdn.com/content/v1/636934fdbb8bde6edeb455cd/d2c39bbb-a288-4707-af0d-0944aa02a811/oncology-dk-kr-article-image-bg-only.jpg)
Announcements from South Korea (SK) to Denmark (DK) pave the way for further outcomes-based contracting for high-cost oncology drugs
Multi-indication and combination therapies are rapidly influencing the oncology marketplace. Faced with increasing treatment complexity and budget demands, payers across the globe are starting to evolve their approach to contracting.